Jazz Pharmaceuticals PLC
JAZZ
Company Profile
Business description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Contact
Waterloo Road
Fifth Floor, Waterloo Exchange
DublinD04 E5W7
IRLT: +353 16347800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,800
Stocks News & Analysis
stocks
Stellar growth from ASX retailer but markets still too optimistic
This Australian success story looks set to face profit margin compression from the scariest of competitors.
stocks
How to focus on the right things this reporting season
For individual investors, it is important to frame earnings season revelations in a long-term way.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,150.30 | 32.70 | 0.36% |
| CAC 40 | 7,753.42 | 54.90 | 0.71% |
| DAX 40 | 24,024.78 | 56.56 | -0.23% |
| Dow JONES (US) | 44,443.16 | 468.07 | 1.06% |
| FTSE 100 | 9,147.81 | 18.10 | 0.20% |
| HKSE | 24,969.68 | 62.87 | 0.25% |
| NASDAQ | 21,658.23 | 272.83 | 1.28% |
| Nikkei 225 | 42,718.17 | 897.69 | 2.15% |
| NZX 50 Index | 12,759.68 | 152.18 | -1.18% |
| S&P 500 | 6,440.40 | 66.95 | 1.05% |
| S&P/ASX 200 | 8,880.80 | 36.00 | 0.41% |
| SSE Composite Index | 3,665.92 | 18.37 | 0.50% |